LUNGevity Foundation shared a post on LinkedIn:
“HER2-mutant NSCLC presents unique challenges in patient identification and treatment selection. Understanding the latest testing approaches and therapeutic options is key to delivering optimal care.
Join our partners PVI, PeerView Institute for Medical Education, for a live in person and virtual session during the 2026 ONS Annual Congress on May 15 at 5:30 PM CDT.
Beth Sandy, Eric K. Singhi, and Jennifer Owens will share practical guidance on integrating HER2-targeted therapies into clinical practice, including patient education, dosing strategies, monitoring, and management of adverse events.
Other articles about Lung Cancer on OncoDaily.